These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 4053141)

  • 1. Effects of bretylium tosylate on inhomogeneity of refractoriness and ventricular fibrillation threshold in canine hearts with quinidine-induced long QT interval.
    Inoue H; Toda I; Nozaki A; Matsuo H; Sugimoto T
    Cardiovasc Res; 1985 Oct; 19(10):655-60. PubMed ID: 4053141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhomogeneity of ventricular refractory period in canine heart with quinidine-induced long QT interval: a comparative study on effects of heart rate, isoprenaline, and lignocaine.
    Inoue H; Toda I; Nozaki A; Matsuo H; Mashima S; Sugimoto T
    Cardiovasc Res; 1985 Oct; 19(10):623-30. PubMed ID: 4053138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ventricular fibrillation threshold in canine hearts with quinidine induced prolonged QT interval: effects of atrial pacing, isoproterenol, and lignocaine.
    Inoue H; Matsuo H; Mashima S; Sugimoto T; Murao S
    Cardiovasc Res; 1986 May; 20(5):349-57. PubMed ID: 3756976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of the effect of bretylium on the ventricular fibrillation threshold in dogs.
    Euler DE; Scanlon PJ
    Am J Cardiol; 1985 May; 55(11):1396-401. PubMed ID: 3993577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of bretylium and clofilium on dispersion of refractoriness and vulnerability to ventricular fibrillation in the ischemic feline heart.
    Kowey PR; Friehling TD; O'Connor KM; Wetstein L; Kelliher GJ
    Am Heart J; 1985 Aug; 110(2):363-70. PubMed ID: 4025111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophysiologic effects of bretylium tosylate on the canine heart during coronary artery occlusion and reperfusion.
    Gibson JK; Stewart JR; Li YP; Lucchesi BR
    J Cardiovasc Pharmacol; 1983; 5(4):517-24. PubMed ID: 6193345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ischemia-induced conduction delay and ventricular arrhythmias: comparative electropharmacology of bethanidine sulfate and bretylium tosylate.
    Kabell G
    J Cardiovasc Pharmacol; 1989 Mar; 13(3):471-82. PubMed ID: 2471895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in canine ventricular fibrillation threshold induced by verapamil, flecainide and bretylium.
    Quesada A; Sanchis J; Chorro FJ; Burguera MA; Alberola A; Such L; Lopez-Merino V
    Eur Heart J; 1993 May; 14(5):712-6. PubMed ID: 8508866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of quinidine and bretylium on defibrillation energy requirements.
    Dorian P; Fain ES; Davy JM; Winkle RA
    Am Heart J; 1986 Jul; 112(1):19-25. PubMed ID: 3728282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bretylium tosylate on ventricular fibrillation threshold during hypothermia in dogs.
    Bjørnstad H; Mortensen E; Sager G; Refsum H
    Am J Emerg Med; 1994 Jul; 12(4):407-12. PubMed ID: 8031422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of effect of bretylium tosylate on electrical ventricular defibrillation in a controlled study.
    Koo CC; Allen JD; Pantridge JF
    Cardiovasc Res; 1984 Dec; 18(12):762-7. PubMed ID: 6518459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrophysiologic effects of bretylium on canine ventricular muscle during acute ischemia and reperfusion.
    Fujimoto T; Hamamoto H; Peter T; McCullen A; McCullen A; Melvin N; Mandel WJ
    Am Heart J; 1983 Jun; 105(6):966-72. PubMed ID: 6858845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deleterious effects of bretylium on hemodynamic recovery from ventricular fibrillation.
    Euler DE; Zeman TW; Wallock ME; Scanlon PJ
    Am Heart J; 1986 Jul; 112(1):25-31. PubMed ID: 3728284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifibrillatory action of bretylium: role of the sympathetic nervous system.
    Kopia GA; Lucchesi BR
    Pharmacology; 1987; 34(1):37-47. PubMed ID: 3575413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmyocardial infarction re-entrant ventricular arrhythmias in conscious dogs: suppression by bretylium tosylate.
    Patterson E; Gibson JK; Lucchesi BR
    J Pharmacol Exp Ther; 1981 Mar; 216(3):453-8. PubMed ID: 7205624
    [No Abstract]   [Full Text] [Related]  

  • 16. Bretylium tosylate: profile of the only available class III antiarrhythmic agent.
    Anderson JL
    Clin Ther; 1985; 7(2):205-24. PubMed ID: 3886143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of propafenone, quinidine, and their combination on ventricular fibrillation threshold in dogs].
    Lu F; Zhang XM; Mei BY
    Zhongguo Yao Li Xue Bao; 1992 Jul; 13(4):364-7. PubMed ID: 1456063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of chronic canine ventricular tachyarrhythmias with bretylium tosylate.
    Patterson E; Gibson JK
    Circulation; 1981 Nov; 64(5):1045-50. PubMed ID: 7285294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bretylium tosylate: a newly available antiarrhythmic drug for ventricular arrhythmias.
    Heissenbuttel RH; Bigger JT
    Ann Intern Med; 1979 Aug; 91(2):229-38. PubMed ID: 380436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antiarrhythmic and antifibrillatory actions of bretylium and its o-iodobenzyl trimethylammonium analog, UM-360.
    Kniffen FJ; Lomas TE; Counsell RE; Lucchesi BR
    J Pharmacol Exp Ther; 1975 Jan; 192(1):120-8. PubMed ID: 1123718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.